Reimbursement FAQs Articles
The COVID-19 pandemic that has pushed the U.S. healthcare system to its limits and crippled the economy has brought stark attention to the need for new legislation to lower medication prices.
Life during the COVID-19 pandemic is surreal even after a year. Healthcare organizations are being pressured to do more with less while at the same time contribute revenue to whittle away at staggering losses.
Two court rulings and segments of the proposed OPPS/ASC and PFS rules may require action from providers to recover expenses caused by the COVID-19 pandemic.
While focusing on being prepared, safe and innovative during the COVID-19 pandemic, healthcare providers mustn’t overlook the critical importance of data integrity.
The Centers for Medicare and Medicaid Services (CMS) released its final rule requiring hospitals to disclose payer-specific negotiated rates effective Jan. 1, 2021. Becoming familiar with the rule’s definitions will assist in making necessary changes to be compliant.
The glut of soon-to-expire products within the pharmaceutical supply chain is a costly problem impacting multiple stakeholders, but smart technology and innovative inventory management systems offer cost-saving solutions.
Healthcare costs continue to rise and payment models subsequently evolve, payers nevertheless largely decide which expensive high-investment drugs will be reimbursed and under what circumstances.
